USPTO serial 99374803
HYPERSYNAPTIKX
Reviewed by CopyMark Law Group
Status 774
- Filing date
- Status date
- Registration date
- —
- Examiner
- GEARHART, JESSICA SHEA
- Law office
- PUBLICATION AND ISSUE SECTION
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with HYPERSYNAPTIKX?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Scottsdale, AZ, US
Scottsdale, AZ, US
Goods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Plates, glass slides or chips having multi-well arrays that can be used in chemical analysis, biological analysis or patterning for scientific, laboratory or medical research use; Sensor chips for scientific use | ACTIVE | — |
| 042 | Drug discovery services; Pharmaceutical products development; Pharmaceutical research services; Pharmaceutical product evaluation; Pharmaceutical drug development services; Pharmaceutical research and development; Development of pharmaceutical preparations and medicines; Technical research in the field of pharmaceutical studies; Research and development services of new pharmaceutical products; Research and development in the pharmaceutical and biotechnology fields; Research and development services in the field of pharmaceutical preparations; Pharmaceutical research in the field of therapeutic discovery and development; Testing of pharmaceuticals; Laboratory research services relating to pharmaceuticals; Research on the subject of pharmaceuticals; Laboratory research in the field of pharmaceuticals; Development of pharmaceuticals for cell and gene therapies; Testing of pharmaceuticals for cell and gene therapies; Testing, inspection or research of pharmaceuticals, cosmetics or foodstuff; Providing medical research information in the field of pharmaceuticals; Providing scientific research information in the field of pharmaceuticals; Conducting early evaluations in the field of new pharmaceuticals; Providing medical and scientific research information in the fields of pharmaceuticals and genetics; Laboratory services for the production of pharmaceuticals in the nature of testing of pharmaceuticals; Research and development of pharmaceuticals for the treatment of age-related diseases and cancer; Providing medical and scientific research information in the field of pharmaceuticals and clinical trials; Research and development services in the field of antibodies; Medical research; Medical research services; Medical research laboratory services; Medical research in the field of oncology; Medical research in the field of pathology; Medical research in the field of infectious diseases; Medical research in the field of rare diseases; Medical research services in the field of cancer; Medical research laboratory services in the field of oncology; Research and development services in the field of medical preparations; Scientific research for medical purposes in the area of cancerous diseases; Providing information about medical research in the field of therapeutic discovery and development; Medical and scientific research in the field of cancer treatment and diagnosis; Technology research in the field of therapeutic discovery and development; Medical research in the field of therapeutic discovery and development; Research and development in the field of therapeutic discovery and development; Scientific research for medical purposes in the field of therapeutic discovery and development; Medical and scientific research in the field of therapeutic discovery and development; Medical and scientific research information in the field of therapeutic discovery and development; Laboratory services for biomanufacturing; Laboratory services for biomanufacturing of antibodies, peptides, and proteins for therapeutic evaluation; Biological research; Biological research and analysis; Biological research laboratory services; Biological research in the field of therapeutic discovery and development; Research in the field of synthetic biology; Biomedical research services; Biomedical research in the field of therapeutic discovery and development; Biotechnology research; Research and development in the field of biotechnology; Research and development services in the field of biotechnology; Biotechnology research in the field of therapeutic discovery and development | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 28, 2026 | ETOP | EXTENSION OF TIME TO OPPOSE PROCESS - TERMINATED | — |
| Oct 27, 2026 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Jul 14, 2026 | ETOF | EXTENSION OF TIME TO OPPOSE RECEIVED | — |
| Jun 30, 2026 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jun 30, 2026 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jun 24, 2026 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Jun 3, 2026 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Jun 3, 2026 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Jun 3, 2026 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Jun 3, 2026 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Jun 3, 2026 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Jan 28, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 28, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 28, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jan 26, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jan 25, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Sep 4, 2025 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Sep 4, 2025 | NWAP | NEW APPLICATION ENTERED | — |